Sun Pharma to acquire DUSA Pharmaceuticals
A 100 per cent subsidiary of Sun Pharmaceutical Industries will commence a tender offer for all of the outstanding common stock of…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Category
Latest Updates
Indegene to acquire marketing services business assets of Canada-based Aptilon
To help clients accelerate their physician engagement strategies
Cipla announces major price reduction on select cancer drugs
Cipla Palliative Care Centre completes 15 years of caring for advanced stage cancer patients
Sun Pharma to acquire DUSA Pharmaceuticals
DUSA’s Levulan combination therapy is for treatment of non-hyperkeratotic actinic keratoses
Quintiles study confirms validity of data from patients recruited over Internet
Lays foundation for direct-to-patient studies using patient reported outcomes + medical record methods
Novartis phase III study shows RLX030 improved symptoms and reduced deaths by one-third in patients…
RLX030 is the first in a new class of medicines and the only agent to show a reduction in mortality in AHF
IKP Knowledge Park announces Grand Challenges exploration
The goal of the IKP-GCE programme is to empower ideas that will create new drugs, diagnostics, devices, vaccines, delivery systems…
Pharmexcil expects Ministry notification on branding for drug exports within a week
Notification to clarify status and expected to bring relief to pharma exporters
Glenmark Generics announces settlement of Paragraph IV litigation with Janssen Pharmaceuticals
Glenmark will launch a generic version of ORTHO TRI-CYCLEN LO tablets as early as December 31, 2015
Cipla announces Q2 FY 12-13 unaudited financial results
Gross revenues grew by 23.6 per cent to Rs 2,220 crore
Indoco Remedies posts 13.5 per cent revenue growth in Q2 of FY 2012-13
Net revenues were at Rs.1645.3 million
CDSCO drafts guidelines on recall and rapid alert system for drugs including biologics and vaccines
Targets to enforce in the next three to four months
Biocon delivers healthy growth in H1FY13
Research services and branded formulations propel strong growth
Aarti Industries posts Rs 28.26 crore net profit for Q2 FY13
Board declares interim dividend of Rs 1.50 per equity share of Rs 5 each
TauRx Therapeutics initiates two global Phase III clinical trials in mild to moderate Alzheimer’s…
The studies may provide the first definitive data on a Tau-based approach to disease-modifying and preventative treatment of…
Novartis to construct biotechnology facility in Singapore with an investment of over $500 million
Construction of new production facility to start in early 2013 and expected to be fully operational by the end of 2016